🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Andreas Halvorsen’s ORKA Holdings & Trades

First Buy
Q3 2025
Duration Held
2 Quarters
Largest Add
Q3 2025
+2.67 M Shares
Current Position
2.67 M Shares
$80.83 M Value

Andreas Halvorsen's ORKA Position Overview

Andreas Halvorsen (via Viking Global Investors Lp) currently holds 2.67 M shares of Oruka Therapeutics, Inc. (ORKA) worth $80.83 M, representing 0.21% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Andreas Halvorsen has initiated a new position in ORKA, representing a fresh investment thesis on this company.

Analysis based on 13F filings available since 2013 Q2

Andreas Halvorsen's Oruka Therapeutics (ORKA) Holding Value Over Time

Track share changes against reported price movement

Quarterly Oruka Therapeutics (ORKA) Trades by Andreas Halvorsen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2025 +2.67 M New Buy 2.67 M $19.23

Andreas Halvorsen's Oruka Therapeutics Investment FAQs

Andreas Halvorsen first purchased Oruka Therapeutics, Inc. (ORKA) in Q3 2025, acquiring 2,666,690 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Andreas Halvorsen has held Oruka Therapeutics, Inc. (ORKA) for 2 quarters since Q3 2025.

Andreas Halvorsen's largest addition to Oruka Therapeutics, Inc. (ORKA) was in Q3 2025, adding 2,666,690 shares worth $51.28 M.

According to the latest 13F filing for Q4 2025, Andreas Halvorsen's firm, Viking Global Investors Lp, owns 2,666,690 shares of Oruka Therapeutics, Inc. (ORKA), valued at approximately $80.83 M.

As of the Q4 2025 filing, Oruka Therapeutics, Inc. (ORKA) represents approximately 0.21% of Andreas Halvorsen's publicly disclosed stock portfolio, making it one of their key holdings.

Andreas Halvorsen's peak holding in Oruka Therapeutics, Inc. (ORKA) was 2,666,690 shares, as reported at the end of Q3 2025.